Nino Rainusso

Nino Rainusso

Auto-generated profile, based on publicly available information

Nino Rainusso

Baylor College of Medicine 14 Houston, Texas

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2013 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
NRNino Rainusso
Nino Rainusso
LWLisa L. Wang
Lisa L. Wang
Jason YusteinJason Yustein
Jason Yustein

15 April 2025 in Circulation
Verified
Journal Article
Closed access
TRThomas D. Ryan
Thomas D. Ryan
JBJames E. Bates
James E. Bates
KKKaren E. Kinahan
Karen E. Kinahan
KLKasey J. Leger
Kasey J. Leger
DMDaniel A. Mulrooney
Daniel A. Mulrooney
OCon behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
on behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and dose reduction, use of cardioprotection for anthracyclines, and modern radiotherapy approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles. Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease.

11 December 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
NRNino Rainusso
Nino Rainusso
HCHeather Cleveland
Heather Cleveland
JHJ. Alberto Hernandez
J. Alberto Hernandez
NQNorma M. Quintanilla
Norma M. Quintanilla
JHJohn Hicks
John Hicks
JYJason T. Yustein
Jason T. Yustein

29 December 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
BJBrittany E. Jewell
Brittany E. Jewell
AXAn Xu
An Xu
DZDandan Zhu
Dandan Zhu
MHMo-Fan Huang
Mo-Fan Huang
LLLinchao Lu
Linchao Lu
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee
Rothmund-Thomson syndrome (RTS) is an autosomal recessive genetic disorder characterized by poikiloderma, small stature, skeletal anomalies, sparse brows/lashes, cataracts, and predisposition to cancer. Type 2 RTS patients with biallelic RECQL4 pathogenic variants have multiple skeletal anomalies and a significantly increased incidence of osteosarcoma. Here, we generated RTS patient-derived induced pluripotent stem cells (iPSCs) to dissect the pathological signaling leading to RTS patient-associated osteosarcoma. RTS iPSC-derived osteoblasts showed defective osteogenic differentiation and gain of in vitro tumorigenic ability. Transcriptome analysis of RTS osteoblasts validated decreased bone morphogenesis while revealing aberrantly upregulated mitochondrial respiratory complex I gene expression. RTS osteoblast metabolic assays demonstrated elevated mitochondrial respiratory complex I function, increased oxidative phosphorylation (OXPHOS), and increased ATP production. Inhibition of mitochondrial respiratory complex I activity by IACS-010759 selectively suppressed cellular respiration and cell proliferation of RTS osteoblasts. Furthermore, systems analysis of IACS-010759-induced changes in RTS osteoblasts revealed that chemical inhibition of mitochondrial respiratory complex I impaired cell proliferation, induced senescence, and decreased MAPK signaling and cell cycle associated genes, but increased H19 and ribosomal protein genes. In summary, our study suggests that mitochondrial respiratory complex I is a potential therapeutic target for RTS-associated osteosarcoma and provides future insights for clinical treatment strategies.

6 June 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ISIrtisha Singh
Irtisha Singh
NRNino Rainusso
Nino Rainusso
LKLyazat Kurenbekova
Lyazat Kurenbekova
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
JDJuan Dou
Juan Dou
Jason YusteinJason Yustein
Jason Yustein
Osteosarcoma is the most common primary malignant bone tumor affecting the pediatric population with a high potential to metastasize. However, insights into the molecular features enabling its metastatic potential are limited. We mapped the active chromatin landscapes of osteosarcoma tumors by integrating histone H3 lysine–acetylated chromatin state (n = 13), chromatin accessibility profiles (n = 11), and gene expression (n = 13) to understand the differences in their active chromatin profiles and their impact on molecular mechanisms driving the malignant phenotypes. Primary osteosarcoma tumors from patients with metastasis (primary met) have a distinct active chromatin landscape compared with those without metastasis (localized). This difference shapes the transcriptional profile of osteosarcoma. We identified novel candidate genes, including PPP1R1B, PREX1, and IGF2BP1, that exhibit increased chromatin activity in primary met. Loss of PREX1 in primary met osteosarcoma cells significantly diminishes osteosarcoma proliferation, invasion, migration, and colony formation capacity. Differential chromatin activity in primary met is associated with genes regulating cytoskeleton organization, cellular adhesion, and extracellular matrix, suggesting their role in facilitating osteosarcoma metastasis. Chromatin profiling of tumors from metastatic lung lesions shows increased chromatin activity in genes involved in cell migration and Wnt pathway. These data demonstrate that metastatic potential is intrinsically present in primary met tumors, with cellular chromatin profiles further adapting for successful dissemination, migration, and colonization at the distal site. Implications: Our study demonstrates that metastatic potential is intrinsic to primary metastatic osteosarcoma tumors, with chromatin profiles further adapting for successful dissemination, migration, and colonization at the distal metastatic site.

22 December 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
EYElizabeth Peale Young
Elizabeth Peale Young
WCW. Susan Cheng
W. Susan Cheng
MBMelanie Brooke Bernhardt
Melanie Brooke Bernhardt
LWLisa L. Wang
Lisa L. Wang
NRNino Rainusso
Nino Rainusso
JFJennifer Foster
Jennifer Foster